GlassScriptPhysician profile
Jonathan M Vapnek
NPI 1558367771
$15,688.70
in general payments reported to CMS, 2019-2025
32 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,666 · 2020: $3,629 · 2021: $1,290 · 2022: $842 · 2023: $776 · 2024: $668 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.65 |
| Education | $104.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $10,214.13 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $845.94 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $822.10 | 2019-2025 | Erleada |
| Allergan, INC. | $580.21 | 2019-2022 | |
| Abbvie INC. | $526.89 | 2020-2023 | Botox |
| Neotract INC. | $466.83 | 2019 | |
| Urovant Sciences INC | $407.07 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $229.74 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $229.73 | 2023-2025 | Pylarify |
| Myovant Sciences INC. | $209.85 | 2021-2022 | |
| Dentsply Ih Ab | $135.15 | 2023-2025 | Lofric, Lofric |
| Antares Pharma, INC. | $131.01 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Ferring Pharmaceuticals INC. | $124.28 | 2019-2020 | |
| Blue Earth Diagnostics | $87.64 | 2021-2023 | |
| Azurity Pharmaceuticals, INC. | $74.52 | 2024-2025 | Azmiro, Horizant |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $73.70 | 2023-2025 | Titan |
| Tolmar, INC. | $69.70 | 2023-2024 | |
| Boston Scientific Corporation | $61.25 | 2019 | |
| Urogen Pharma, INC. | $52.30 | 2025 | |
| Halozyme INC | $48.64 | 2023 | |
| Intuitive Surgical, INC. | $39.14 | 2021 | |
| Dentsply Ih INC. | $38.75 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $32.68 | 2019 | |
| Abc Home Medical Supply, INC. | $27.40 | 2025 | |
| Merck Sharp & Dohme LLC | $24.10 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $23.97 | 2022 | |
| Pfizer INC. | $23.79 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.01 | 2022 | |
| Hollister Incorporated | $19.78 | 2019 | |
| 180 Medical, INC. | $16.95 | 2021 | |
| Clarus Therapeutics INC. | $14.39 | 2021 | |
| Metuchen Pharmaceuticals | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Vapnek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.